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HOW TO READ
"SCIENCE vs. AIDS"
This publication is produced to be read in ·two different
ways. On the righ! side of the pamphlet are the highlights of
the Seven Springs conference proceedings written 'in non
technical language. On the left side are easy-to-understand
summaries of several key scientific issues · pertaining to the
AIDS epidemic. This background is intended to provide
readers with the basic information necessary to help them
comprehend the complex task facing scientists as they work to
understand the AIDS virus and develop treatments against it.
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PREFACE
I

n the spring of 1988, my laboratory colleague Professor
Ralph Steinman and I were hosts to a small group of fellow
scientists at a meeting at Seven Springs, The Rockefeller
Universitys conference center in Westchester, New York, a
quiet enclave some forty-five minutes north of the University's
Manhattan campus.
The thirty-one participants, representing a number of dif
ferent disciplines and institutions, had in common that each
is a leader in research that bears directly or potentially on the
problem of AIDS. Our object was to spend a couple of days
together, free from the intrusions of the laboratory, the clinic,
and the press, sharing our ideas and the perspectives derived
from our individual investigations in an attempt to assess
where we are in understanding this terrible disease, and
where our future efforts should be directed.
While the meeting was being planned, it was suggested to
us that a report of our discussions would be of interest· to
many people outside the research community. We invited
science writer Lois W ingerson to att�nd the meeting and
prepare this publication. (A scientific summary of the meeting
by Dr. Steinman and myself appeared in the December 1988
issue of the Journal of Experimental Medicine.)
We would like to express our appreciation to Rockefeller
University Council member Katherine Morgan Deane, and to
Rockefeller University trustee Disque Deane for their gener
ous support of the Seven Springs project.
ZANVIL A. COHN

I

Henry G. Kunkel Professor
The Rockefeller University
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Lymphocytes as seen with
a scanning electron micro
scope, which magnifies
actual sizes 1,600 times,
and provides a high reso
lution view of the contours
of the lymphocyte surface.
However, microscopy does
not reveal the chemical and
functional differences that
exist among lymphocytes.
About half the lympho
cytes in human blood
carry a surface molecule
called T4 or CD4. CD4bearing lymphocytes make
molecules called lympho�
kines (or interleukins)
which help generate im
munity. It is the malfunc
tion and loss of CD4
helper cel ls that is so seri
ous in AIDS.
8
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INTRODUCTION

W

hat we already know about the acquired immune defi
ciency syndrome fills thousands of pages in scientific
journals, but it is not nearly enough. There is no cure in sight,
and the epidemic continues to spread.
AIDS is still eluding scientists because it is an entirely new
challenge-caused by a kind of virus new to medical science,
infecting a complex network of human cells that is still poorly
understood. Meeting this challenge demands a diverse mix
ture of scientific specialists, people who have had little reason
to pool their expertise in the past. Now there is a most urgent
reason, and in May 1988, there was an opportunity.
For two days, a small group of top AIDS researchers met in
seclusion at a conference center in Mount Kisco, New York. It
was an event unique in the history of AIDS research. There
were no press reports, no audience, no formal presentations,
no strict agenda; just thirty-two scientists and a slide projector
in the small library of an old estate. Their deliberations remain
as pertinent now as they were at the time of the conference.
The sponsors from The Rockefeller University had invited
the participants to the Seven Springs Conference Center to
address a few basic questions: What do we know about AIDS,
and what do we still need to learn? Which questions can be
answered, and how? Which questions cannot be answered at
all?
The decisions came from different vantage points. A few
participants were medical researchers who encounter AIDS
patients daily. Others had rarely if ever seen an AIDS patient,
but spend their days studying cells in laboratory dishes. Some
set their focus even deeper, on the molecules inside viruses
and cells.
The retrovirologists at the conference had spent years in an
esoteric endeavor, studying a class of viruses not known be
fore 1980 to infect human beings. When the AIDS virus joined
the class, the work of these scientists was suddenly pivotal. A
few people in attendance had not studied AIDS at all, but had

SCIENCE vs. AIDS: Defining the Battle Lines
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(left to right)
Dr. Alan Williams and
Dr. Robert North

Dr. Bernard Fields

(left to right)
Dr. Jay A . Levy and
Dr. Malcolm A. Martin
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Below left: Dr. Richard
Lerner and Dr. Hilary
Koprowski (below right)
Dr. Anthony Fauci,
Dr. David K latzman and
Dr. Samuel Broder

focused on the normal immune system which counteracts
diseases inside the human body-and which the AIDS virus
invades and destroys.
Exactly a month after the Seven Springs meeting, the chair
man of a much larger gathering-an international AIDS con
ference in Stockholm-would tell his audience of 7,000 that
the news about AIDS was "even more frightening than we
have expected." Indeed, the press reports were grim:
On average, it takes about eight years after initial infection
to develop the first signs of AIDS. Eight years after the first
reported cases, therefore, the full impact of the disease was
just beginning to be evident. It might be even worse than it
appeared: In some individuals, according to a new kind of
test, the virus seemed to hide out inside cells without even
causing an immune response that can be recognized in a
blood test. Once infected, a person's odds of survival-speak
ing very optimistically-may be one percent.
The scientists meeting at Seven Springs knew all this �
month earlier, but their consensus for the future seemed less
grim than the press reports that would come from Stockholm.
Much does remain to be done before the AIDS crisis is
solved. That fact has a mirror image, reflected at the Seven
Springs conference: Much can be done.

AIDS

(left to right)
Dr. Siamon Gordon and
Dr. Irving Weissman

(left to right)
Dr. Alain Pompidou and
Dr. Martin S. Hirsch

(left to right)
Dr. William A. Haseltine
and Dr. Michael Oldstone
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ORIGINS: OBSCURE
t is tantalizing, but probably futile, to ask how AIDS began.
The AIDS virus shows similarities to some viruses prevalent
in African monkeys, and one theory holds that it spread to a
human being from a monkey, perhaps as recently as the
second half of this century. But evolutionary studies from
Japan suggest that the difference between the AIDS virus and
its simian relatives dates back much farther, perhaps thou
sands of years. Then why did it gain a·foothold as a disease
probably no earlier than 1960 (to judge from studies of stored
blood)?
We may never know. The same question can be asked about
the microorganisms that cause bubonic plague, or polio, or
rheumatic fever, or the agents that may cause arthritis or
multiple sclerosis. And again there is no good explanation as
to how these diseases arose, where and why, and why they
may wane. The human population has a most unstable truce
with viruses, which are in their own ways as inscrutable and
changeable as we are.

I
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THE SEVEN SPRINGS
INTERNATIONAL
CONFERENCE ON THE
IMMUNOLOGICAL AND
INFECTIOUS SEQUELAE
OF AIDS:· A SUMMARY

T

he adversary is incapable of designing strategies. It does
not understand malevolence. But for everyone who thinks
about the AIDS virus-including the scientists who know it
best, gathered at Seven Springs-it is almost irresistible to
regard the virus as a deliberately crafty and insidious enemy.
Its name describes its methods: human immunodeficiency
virus, or HIV Actually, there are two forms of the AIDS virus,
HIVl and HIV2, which have some structural differences but
similar disastrous effects. At the outset, the conversation at
Seven Springs centered on viral guerilla tactics: the ways in
which HIV commandeers and disarms the very immune cells
that ought to discover and destroy it.
In one sense, scientists already know HIV inside and out.
Inside, a core of proteins and molecules of genetic material,
RNA. Outside, a coat of glycoprotein, protein wrapped in
sugar. (See page 42.) Researchers have no trouble recognizing
HIV in the laboratory, using molecular ID tags called antibod
ies, which an animal's immune system will manufacture in
response to HIV's presence in its blood.
In another sense, scientists know almost nothing about
HIV The details of its life history and ordinary affairs remain
a mystery. It is as if the FBI had identified a terrorist group and
possessed photographs, fingerprints, and a good descrip
tion-but had no idea whatever of its whereabouts or
movements.
HIV gives medical science its first good opportunity to
study the interaction of human beings and a class of viruses
previously known only to infect animals, the lentiviruses. It's
a field of study with many scholars, but a history of only five
years.
SCIENCE vs. AIDS: Definin,R the Battle Lines
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BRIEF HISTORY
OF AN EPIDEMIC
At the outset, what we would come to call AIDS was
J-\.merely a disturbiilg, somewhat intriguing, little puzzle.
A few otherwise healthy young American men began to suc
cumb to rare infections they had no business catching: Pneu
mocystis carinii, Mycobacterium avium tyberculosis, diseases
of the Third World or, in the United States, of the old and
debilitated.
In June 1981, 152 such cases were reported in a medical
journal. Nine of ten victims were homosexual or bisexual
young men .. Fortunately, the first suggested name-GRID,
for gay-related immune deficiency-did noMake root. After
1981, the number of cases would double every six months and
reach far beyond the homosexual community.
Another name gained acceptance: acquired immune defi�
ciency syndrome, or AIDS. The syndrome "Yas defined as:
• progressive immune deficiency;
• disseminated infections such as herpes, candidiasis, Pneu
mocystis pneumonia;
• perhaps Kaposi's sarcoma, a tumor of tissues lining blood
vessels and organs, formerly known mostly among older
Italian or Jewish men, or Africans.
1981: The cause of the disease was a matter of speculation.
Under consideration were autoimmunity, damage from
sperm in anal intercourse, recreational drugs favored by
homosexuals or, most likely, a new virus. In general,
most governments and the press treated AIDS as a
curiosity.
1982: Cases had now been reportea from Haiti, Europe, and
Africa. An outbreak of Kaposi's sarcoma erupted in Zam
bia. The diarrhea, fever, and weight loss common among
AIDS patients were · so prevalent in parts of Africa for
other reasons that AIDS was initially very difficult to
pinpoint on that continent.
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A FREE AGENT?
At its start, the Seven Springs conference grappled with
.fl.one of the most troublesome unknowns about HIV:
whether the virus tends to infect cells while it floats freely in
the blood, or whether it always spreads-with one excep
tion-from cell to cell.
The exception is hemophilia, the inherited bleeding disor
der in which blood fails to clot properly. People with hemophi
lia can contract HIV infections if the virus contaminates
preparations of Factor VIII, which they must take to stop
bleeding. This blood fraction, prepared from the concentrated
plasma of many donors, is filtered finely enough to extract
bacteria and whole cells, but not free viruses. The HIV in
Factor VIII must be transmitted as a free agent-but was the
virus freed by the plasma preparation, or was it free in the
donor's plasma in the first place?
Moreover, is such cell-free passage of the virus really an
exception? The answer is elusive, because the free virus is
elusive. People who are infected but not yet ill are likely to
transmit the virus to others, yet it is rare in their body fluids.
The only body fluid where HIV is abundant in cell-free form
is the cerebrospinal fluid that bathes the spinal cord and the
brain-hardly a major route for passage of HIV from one
person to another.
Precisely what, then, is the origin of the infection in the
semen passed in sexual intercourse, or in the contaminated
hypodermic needle which spreads HIV to an intravenous drug
abuser? It's hardly an esoteric question, because a critical one
follows: To control the spread of AIDS, must we prevent pas
sage of free virus, infected cells, or both? And which cells?
"The definitive experiment has yet to be done," said Mal
colm Martin of the National Institute of Allergy and Infectious
Diseases (NIAID). "Every meeting I go to we ask the same
question. No one has the answer."
Finding it will be difficult. Most AIDS patients have been
infected for years before they develop symptoms. Ethically
and practically, it's impossible to study the moment of infec
tion, whether it is during intercourse or a needle prick.

SCIENCE vs. AIDS: Defininiz the Battle Lines
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1983: Intravenous drug abusers, people who have received
blood transfusions since 1978, and people with hemo
philia who take injections of the blood fraction Factor Vill,
were added to the high-risk groups.
During the same year, Luc Montagniers team at the
Pasteur Institute identified a new virus from several
patients with AIDS or with symptoms that precede
the disease.
1984: · Robert Gallo and coworkers at the National Institutes of
Health also identified an AIDS virus (subsequently found
to be very similar to MontaITT"tiers virus). They also devel
oped a way to grow the virus in the laboratory, and both
the American and French laboratories developed tests
that blood banks could use to search for the presence of
the virus in donated blood.
1985: Two simple, grim statistics: By year's end, eighty-three
percent of the first 500 AIDS patients in San Francisco had
died. Median survival after diagnosis was eleven months.
In April, widespread screening of donated blood began
in the United States to exclude units contaminated with
the AIDS virus.
1986: Now the virus that causes AIDS had its own monogram:
HIV (for human immunodeficiency virus). In clinical
trials, the antiviral drug AZT was shown to slow, but not
arrest, the immune destruction in AIDS. A study of AIDS
in Florida found no evidence to support the fear that
AIDS might be spread by mosquitoes.
1987: Concern was rising that the risk of AIDS transmission
among American heterosexuals might ultimately be as
high as that being documented in Africa. The concern
might be overemphasized, but it was not trivial: AIDS
was now the leading cause of death among intravenous
drug abusers and hemophiliacs, both groups that include
many heterosexuals. Thirty percent of America's 1.1 mil
lion intravenous drug abusers are female, and half of
these women have a history of prostitution.
Meanwhile, human testing of two potential AIDS vac
cines and widespread use of AZT were approved for
AIDS patients.
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With this issue, there arose in the first minutes of the Seven
Springs conference the most frus,trating aspect of AIDS re
search: the lack of an ideal animal model. Although a virus
that infects some monkeys has many similarities to HIV, and
although mice have been genetically engineered to have HIV
in every cell of their bodies, direct infection with HIV itself
does not cause a disease like AIDS in any species other than
human beings.
A scientist studying the common cold can ask volunteers to
submit to applications of a virus in the interests of science; the
consequences are uncomfortable but mundane. Obviously,
such experiments are out of the question for an AIDS re
searcher. What then?
Recently, a virus very similar to HIV has been shown to
cause a disease very similar to AIDS in rhesus monkeys, and
this is extremely promising as an animal model for AIDS. But
to date, most researchers have had to resort to less than
optimal methods in addressing basic questions about the
AIDS virus. Even with the rhesus monkey model, some ques
tions-such as the precise mode of entry of HIV into the
body-may be unanswerable.
Most of what scientists know about the AIDS virus, beyond
watching the progress of the illness itself, has been gained
from studying human cells persuaded to grow in laboratory
dishes. How much of the ''knowledge'' gained in this artificial
manner is irrelevant? (As one conference participant put it: "A
human being is not a tissue culture!") Without a good animal
model, many theories about HIV will remain nothing more
than best guesses.
"We have to be honest with each other," interjected another
participant early during the first session. "Instead of kidding
ourselves, somebody ought to take down the message that the
one thing we do know is that we don't know.''
"We do know things about the pathway," countered the
session chairman, Bernard Fields of Harvard Medical School.
''We know some of the genes. We often don't know why the
virus goes in a certain pathway. There are enormous gaps in
the complexity of the biology. In so many places, we can't
[obtain] rigorous biochemical proof of a mechanism. But we
do not know nothing!"
SCIENCE vs. AIDS: Defining the Battle Lines
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1988: Eight years after AIDS was first recognized, it is still
SYIJonymous with death.
' By the time of the Seven Springs Conference in May,
HIV had spre�d to 111ore Jhan 62,00OAmericans, includ
ing 39,000 homosexuals, 11,000 drug abusers (and 5,000
people who fall into both categories), as well as 600 he
mophiliacs and 1,000 children. Public healtfi experts pre
dict that by the end of 1993 some 450,000Americans will
haveAIBS.
How bad an epidemic isAIBS? For comparison, every
year in the United States, approximately:
1,000,000 people.are diagnosed with cancer
900,000 people have their first,heart attack.
150,000 people develop Z-ung cancer
50,000 people die in highway'accidehts
. Worldwide, .more than 81,000 .AIDS cases have been
reported in 133 countries. An AIBS expert at the World
Health Organiz.ation says the real incidence is probably
twice as high. By 1990, it is estimated, more than a million
people will suffer from the disease.
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MEANS OF ENTRY

H

,_

owever it gains access to the body, HIV has to enter a
human cell so that it can reproduce. It must invade the
cell's genetic machinery and use it for its own replication.
Which cell does it choose?
Evidently, HIV most often gains access to certain of the
white blood cells: the helper T cells, the monocytes, and
macrophages. All of these have important functions in the
immune system (see p. 30). New studies suggest that macro
phages may be HIV's first victims inside the body, the refuge
where HIV hides out and multiplies even before provoking an
immune reaction.
At the outset, when AIDS first appeared, researchers fo
cused on HIV's tendency to infect and kill a certain sub
population of the T cells of the immune system. Alan Williams
and Don Mason of Oxford University had recently identified
a unique molecule called CD4 on the surface of helper T cells,
and they used it as a label to distinguish these from other
kinds of T cells. As Mikulas Popovic of the National Cancer
Institute (NCI) reminded the conference, very early AIDS
experiments showed that antibodies which bind to CD4 could
prevent the virus from infecting T cells in the laboratory. When
this emerged, it seemed obvious to assume CD4 was the lock
that HIV could open to enter a T cell.
The revelation that macrophages could also be infected
came later, and brought with it serious implications. Cells of
the macrophage type, and their blood-borne relatives the
monocytes, are everywhere. Macrophages take up long-term
residence in the lining of organs such as the lungs, the kid
neys, and the brain. In all these places, apparently, they are
both housekeepers and nurturers; they produce messenger
chemicals and also take up and degrade cellular debris. If the
virus could infect a macrophage-type cell, it seemed there was
almost no limit to where it might lodge.
Although cells of the macrophage variety do have some
CD4 molecules on their surfaces, there's a mtich simpler
(though as yet unproven) way for HIV to enter: endocytosis,
the natural process by which macrophages engulf and destroy
foreign matter and damaged cells. Does HIV usually infect
SCIENCE vs. AIDS: Defining the Battle Lines
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AT RISK
Male hoµmsexuals: Infectea with HIV via anal intercourse:
Intravenous dry.g abusers: Infected by sharing syrirlge needles

with someone carrying HJY in.his or herb!oodstream.
Hemophiliacs: Infected from contaminated injections of Fg.cto:r'
VIII; taken to avoid uncontrolled bleeding.
Transfusion recipients: Infected by receiving clonorblood con
taminated with MIV. Less tha:ry . two u:ryits, of ( dop�ted
blood in a tl).ousand art� .fou:ryd to be ,infectedby H� �nd
these. units are ·discardeq.. • Becat.1se so.me·· · researchers.
thinl< that the virus; can briefl;y IJ.ide out.in cells withp11t '
provokin'.g antibocli��1. it hasbeen th�J)��ed..thafsoll'.le 46Q
peoJ?le each year might r�ceiy�· •ihfect�q bl9od that· escapes detection. .
.
. . {. . .. .
. them
' ( ;in1/4
Infants of infected moth�rs: rn�eAfIDS x�s reaches
ut�ro, during birth, 0� perhg.ps. ,.while'nur?ing� '
Sexual contac!s o� AIDS. carri�rs:,rye �s apparently caR.be
transmitted during yord�arr hete1:�sext1�l·. in�erc�urse.
. The ac�al risl<· of· cat�hic1�. .,'��S ,�etero�exuglly, �si:,e-- ..
c i al l y f r om a·•·· WOfficlJ.1,.. i� iUn k n o wtra nd trigh ! y·
controvers�al. .
. .;. • ( ·, . , . ... . .
., ..
There i8 no evidenc.� to ·support airy st1ggestion Jhat .
;
AfIDS can be . spreacl by,.< cg.sual: c011tactr kissi11g, < or in-sect bites.
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macrophages via the CD4 receptor, or is it swallowed in the
normal course of events?
That leads to another important unknown. If HIV often
infects macrophages by endocytosis, how can it be stopped?
Should a macrophage be prevented from doing its regular job?
"We can't yet answer what it is about the macrophage that
makes it win or lose against ar�y virus," observed Dr. Fields.
"This is a critical question that is a gap in our information."
The latest type of white blood cell to be implicated as a host
for HIV is the dendritic cell. A principal function of these cells
is to act as accessory to the normal function of CD4-positive
cells. If infected, dendritic cells may interfere with T-cell func
tion, or transmit the virus.
Another troubling puzzle is where, inside the vagina or
rectum, the AIDS virus first lodges after being transmitted
during sexual intercourse. Can an intact vaginal lining be
infected?
The cells on the epithelium, the surface lining, of the vagina
and rectum don't possess the CD4 molecule, the lock that HIV
can open. Does HIV infect these cells through another open
ing (in which case many drugs and vaccines proposed to halt
the infection are useless)? Or must there be some minor injury
during intercourse, which gives the virus access to underlying
cells that do bear CD4 on their surfaces?
The evidence ·is mixed. As Jay Levy of the University of
California, San Francisco, pointed out, studies from Africa
show that the risk of heterosexual infection appears to be
increased in the presence of genital ulcers or of two venereal
diseases, chancroid and chlamydia. All·of these factors could
bring immune cells to the surface, where the virus could reach
them.
On the other hand, both Dr. Levy and Michael Oldstone of
the Scripps Clinic and Research Foundation displayed pic
tures showing evidence of HIV infection in certain cells lining
the intestine and rectum. But are these really macrophage
cells that have taken up residence in the gut, where macro
phages are very common? Photographs alone won't resolve
the issue; further study is needed.
"Some of these questions you'll never be able to answer in
humans," commented Martin Hirsch of Massachusetts GenSCIENCE vs. AIDS: Defining the Battle Lines
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WANTED: ANIMAL MODEL
Acquired immune deficiency syndrome is
unique to human beings. This simple fact,
more than anything else about AIDS, has
slowed efforts to combat the disease.
CHIMPANZEES can be infected with H[V,
but they do not proceed to develop immune
deficiency.
RHESUS MACAQUE MONKE YS can be
infected with the simian immunodefi
ciency virus, SIV, which is closely related
to HIV in its genetic constitution and its
effects. Monkeys infected with SIV may re
main persistently infected or may die of
problems that parallel AIDS. The rhesus
macaque is probably the best animal model
for AIDS available today, and is in great
demand. However, it is too soon to say how
much of what may be learned about SIV
will translate directly to AIDS.
GENETICALLY ENGINEERED MICE, cre
ated at the National Institutes of Health,
contain copies of the AIDS virus in every
cell. They are the only mammals other
than humans that get sick from the effects
of HIV.
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CONGENITALLY IMM UNODEFICIENT
MICE have been implanted with fetal
human thymus, liver, spleen, and lymph
nodes in experiments by Dr. Irving Weiss
man and Dr. Michael McCune at the Stan
ford University School of Medicine. As Dr.
McCune reported these experiments dur
ing the Seven Springs meeting, only four of
these mice had been inoculated with HIV,
and it was too soon to say whether they
might go on to be infected with HIV or
develop a disease like AIDS.
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eral Hospital. "You can't study the individual [infectious]
episode.''
"That question, we can't answer in man," agreed Hilary
Koprowski of the W istar Institute. "We can reconstruct skin
in tissue culture. We can do a lot of experiments and show,
I'm sure, that the virus will get in. But that doesn't mean it
occurs in vivo."
It might be possible, however, to learn why some individu
als remain infection-free despite years of regular sexual con
tact with a HIV-infected partner. There could be elements of
the fluid environment in the human vagina or rectum that
inactivate the virus. These may vary from person to person.
"This area has not been looked at very much," said Dr. Fields.
"It's drudgery to pull this all together, but it's probably
worth it."

VIRUS FACTORIES

T

he fate of a cell infected by HIV depends on its cell type.
It appears that HIV ultimately kills helper T cells, but it
often seems to spare a cell such as a macrophage in order to
use it as a factory, to assemble new versions of itself. Much of
what is known about HIV comes from studies of T cells;
speakers at Seven Springs agreed on an urgent need to repeat
these experiments using macrophages and monocytes.
Inside such a cell, HIV probably behaves much like the other
retroviruses that have been studied in animals (see p. 28). It
allows the cell's enzyme_s to unzip its coat, and proceeds to
use its own enzymes to translate some of its RNA genetic
message into DNA. Then the DNA version of the virus's
blueprint somehow elbows its way into the cell's own genetic
material, where it may sit silently for years.
W hat rouses it into action later, ironically, is probably the
cell's response (in its normal role within the immune system)
to the presence of a further infection. In laboratory dishes,
HIV can be provoked to replicate when ''quiet'' infected cells
are triggered into action by some immune stimulus. For an
AIDS patient, the first sign of the disease is often the appear
ance of a major infection of another kind.

SCIENCE vs. AIDS: Definin� the Battle Lines
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THE IMMUNE NETWORK
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Killer lymphocyte

When a healthy person gets an infection, he
or she can mount an astonishing number of
different kinds of responses to the insult.
Here are examples of the reactions that can
be set off by a microbial invader such as the
measles virus:
Like internal sanitation engineers, the
macrophages wipe up the dead infected
cells, destroying and breaking up the vi
ruses inside. In the process, the macro
phages present viral proteins on their cell
surfaces in a form that T cells can recog
nize. Dendritic cells also can take up anti
gens in tissues where they are deposited.
Their job is to tell the T4 cell that antigen is
present, and to induce the T4 cell to grow
and make lymphokines.
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Antibody-producing
B lymphocyte

Activated helper T cells secrete soluble
factors, known as lymphokines, which halt
the replication of virus and spur the matur
ation of other lymphocytes into killer and
more helper T cells. Cytotoxic T cells kill
virus-infected cells. Helper T cells boost
the action of phagocytes, as well as of the B
cells that create antibodies, soluble Y
shaped structures that recognize foreign
proteins such as parts of a virus's coat.
Gradually, after several weeks, a popula
tion of memory T cells arises, which pre
serves the ability to recognize the defeated
virus, should its relatives ever return.

•.,
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Once the cell is activated, the viral DNA inside it begins to
copy itself and to assemble new AIDS viruses. These collect
inside the surface of the infected cell and eventually ''bud"
out, wrapping themselves in part of the cells glycoprotein
surface before they pull away.
In laboratory dishes, escaping viruses may pepper the sur
face of an infected T cell with holes; it appears to explode. This
makes a dramatic photograph, but is it clinically important?
Just as easily, the virus can spread directly when an infected
cell fuses with an uninfected one-or, in fact, with a large
number of other cells-to form ''giant cells' ' or syncytia. Such
cell fusion is a neat explanation for some of the clinical phe
nomena seen in AIDS patients. Whether cell death or cell
fusion is more important to the immune devastation of AIDS
is still unclear.
What is clear is the resulting devastation to the immune
system. Its routine business requires some cells to touch and
aggregate, and others to travel long distances through the
blood or lymph canals, often homing in on the organs where
immune cells are created or wait at rest-the lymph nodes,
the spleen and thymus, and the bone marrow. Any one of
these cells, infected with HIV, could transmit new viruses to
many other cells.
It's the worst nightmare of an intelligence chief: One agent
turns, and before long the entire system is corrupted. Nobody
knows until it's too late.

SCIENCE vs. AIDS: DefininR the Battle Lines
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AIDS AND SOCIETY
j

f AfDS presents daunting problems tbscience, its challenge
to society is equally · complex-and the reaction has often
been distressing.
The blind eye: In the United States, the most frequent
victims of AIDS are members of outcast groups: homosexuals
and drug addicts, and increasingly a third group, prisoners.
Compared to the polio, epidemic of the 1950s, which spread
across a diverse segment of American culture, it was, at least
initially, far more difficult to raise official and public interest.
(not to mention funds) to combat the AfDS crisis.
The cold shoulder: Unlike polio in the 1950s, AfDS appears
to be unequivocally fatal (until such time as a cure is found).
Many of the unaffected react with fear and hostility. Children
with AfDS have been stigmatized by adults; in one case> a
young AfDS victims house was burned down. Many health
professionals-doctors, nurses, dentists, even morticians-,
avoid contact with AfDS victims. Surveys show that many
who do not shun them fear for their own lives.
The pointing finger: Society grapples with the competing
problems of discrimination and the need'tp know. To mon!tor
and characterize the epidemic, it is urgent to identify which
people have been infected. AfDS testing is already routine in
the US military. Many public figures support mandatory AIDS
tests for various other groups such as immigrants, prisoners,
and marriage applicants. People infected with HIV face two
fights: the fight agaiJ.J.st the virus, •attd the fight against
discrimination.
The underclass: In America, AfDS is most common in the
lower socioeconomic classes, and tends to draw health care
resources (already scarce) away from poor people who have
other problems. As a result of AIDS, public hospitals suffer
shortages of antibiotics;.beds, nurses. Whole wards are t*en
over by infants with AIDS born to drug-abusing mothers; not
enough foster homes can �e found.
The Third World: In part_s of Africa and South America,
AfDS cripples an already weak health-care system. T hat
weakness contributes to the spread of AIDS in tum, because
blood testing is less common than in the United State� ·�11d
Europe, and hypodermic needles are used more than once.

I
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ow this could happen-how HIV can, in time, completely eradicate the immune system-is a baffling issue
that arose again and again at Seven Springs. "The kinetics
[rates of progress] of the immune destruction is really a black
box," said Samuel Broder of the NCI. "Many things about the
clinical course are very complicated and difficult to under
stand, including the initial infection which does not lead to a
sudden, fulminant T-cell depletion.''
The latent periods-extended episodes of general health
despite HIV infection-are characteristic of the disease. The
virus may seem to be hiding out, because no one is aware of
it, but is it really inactive?
In the laboratory, resting T cells or monocyte/macrophages
appear relatively resistant to infection. And once infected,
monocytes will not release new viruses without being acti
vated by an immune-system stimulator, noted Anthony Fauci
of NIAID. But are these latent cells an artifact of the
laboratory?
Dr. Martin raised the question of what is a truly resting cell.
The virus itself carries substances that may activate an im
mune cell to respond as if it had detected a new infection. If
such a cell is already heavily infected with HIV, the presence
of these substances in themselves may provoke the manufac
ture and release of new viruses from the cell.
"My own feeling is that we need to differentiate a single cell
or a population of cells from the whole individual," remarked
Robert Gallo of the NCI. "In the whole human, there is no
time when you do not, find expression [production of new
viruses] in some cell. It may be very small at times, but in a
pool of 100,000 cells, you almost always find some expressing
the virus.''
On average, noted Dr. Fauci, at most one of every 1,000
white blood cells in an AIDS patient appears to be infected by
HIV, according to the most sensitive test. Only one of every
10,000 or even 100,000 is actively producing new viruses. Yet
even early in the disease, while a patient appears to_be well,
the population of T cells steadily declines. It's very puzzling.
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T.

he ·cours¢ of AIDS. vatje� wi<l.eljr, "from; patj:ent t<? patient ·:
Only; cme feature seemsmvanant: fatality.. :'
·.
The incubation period of�II)p_:_the ipter�albehveen infec�
tion .with tfie •· virus and orisetbf serious· tlisease""7is about
eight years among. adul�s: Someo11e·infected by thf�s may.
notice a flulike epis.ode and a pe,rioa of weakne�s and lethargy
shortly after infection; butwill/'ecoyer to remain ·"healtfiy" for.
some years..
A.fter a brief period, peoJ?le iD:fected with IBV dndevefop
an immune· response to the virus/indwiing.the proquctio11 of
antibody molecules that' recognize. many constituents . of the
virus ·including. its\prQtein.coat.. Theseantib dies ..allow· the
presence of the.virus tobe documentec(,butthey do not stop·
the disease.
During the relatively longfafel}f JJeriod, a· JJart of the JJa
tiel}ts immune,System begins to aeJJlet� raJJidly. Irt JJarticular,
_ certain immune cells· KnOWl). as''t4 helJJer cells,· in1pm:fant il}
·marshafiing the immlllle system.to.,f.ighfinfecfions; decline
JJreciJJitously. The mechanism unoerl)1ng the Joss of. Li cells
is still·not clear:
.
A.t the same timer JJI"Obably so . · . .. . er the infection, many
·
. JJatients begin to experience· psycho!9gka�problems
�.uch as
.aJJathy, lacl< 9f coordination,.and cHffiqulty'°in·comJJletihg or
dinary .taSKS. These JJFOblems may be subtle/or·may}Jrogress
to fraliK dementiawith alarm.ing.sJJeed.·For eighty.percent of
JJatiehts witn signs of brain ·:infection, ·full�blo
. wn dementia
develops within a year.. .
. .· .
. .. . . . . .
Sooner . or fater . the im.mune
.·· deJJleti9n ...a.l�o ,. has conse
quences.,Many patients deyelopKaJJ OSis sarcoma, a· disfigyr
ing an d dissemin ated can cer.primarily of · t h e sl<in.
Interestingly, ·· recent s�die� suggest .. ·tha.t.the. incidence of
.Kaposis is declining among Afnericanswith AfDS.
A. ffiore sigrrificant 8SJJeCf?fthe fi11al ·d�cline in.�IDS is the .
relentless JJrogression of''opJJortunistic't,infections/atta�ks.of ·
illness due to fungi oFl:,acteria that a healtfiy immune system
couldcontrol w
· ithotit trouble..� (The.. �9st JJ.ronririent.is �ne11:
mocy·stis carinii gneumoni�, a lu11g .inteFtton �ormerly.most
cqmmon among ca,ncer JJc:ltients ana transplal}t reciJJientswho
·are weakened by immundSURJJFessive medications) The o:r34
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"Those of us who follow AIDS patients for years see them
completely run out of T cells," he said. "We still haven' t
explained how you ultimately, completely, run out of T cells.
I' ve been in many discussions, and this has never been
resolved.' '
Nothing in medical history appears relevant to the question.
The scientists at the conference searched for a good analogy
that might provide some explanation: Organ transplant pa
tients treated with immunosuppressive drugs? People with
the autoimmune disease myasthenia gravis, who have had
the thymus (the organ where T cells arise) removed as a
treatment? Bone marrow donors? None of these people com
pletely run out of helper T cells, as an AIDS victim inevitably
does.
There are a number of possible explanations. Recent studies
show that HIV becomes more virulent (more infectious and
more deadly to cells) as the disease progresses. It is also
possible that the immune system contributes to its own de
struction, by killing infected cells.
The fusion of infected cells with uninfected ones is another
attractive explanation. Both in lab dishes and in monkeys,
giant cell agglomerations called syncytia arise in the presence
of HIV. In the laboratory, these syncytia die about a day after
they form.
However, the syncytia that appear under laboratory condi
tions are arising in clones of T cells that have grown up from a
single ancestor blood cell and may be only distant descendants
of the cell that once traveled in a human's bloodstream. Who
can know how they may have been altered in the process of
adapting to laboratory conditions? Depending on the condi
tions in cell culture, noted William Haseltine of Harvard Med
ical School, scientists can "push" HIV-infected cells to either
form syncytia or swell and burst.
"There's a very complicated, dynamic situation going on,"
he said. ''There are a whole series of factors to consider, which
will determine if you see syncytia, cell death, or continuously
virus-producing cells."
Medical researchers rarely see large numbers of syncytia in
the lymph nodes or spleens of patients. Even if syncytia do
form at some stage of the disease, it is not obvious when or
where to look for them. Are they really important in the
disease?
SCIENCE vs. AIDS: Defining the Battle Lines
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HOMING IN ON

THE SOURCE

T

he explanation for the depletion of T4 cells may not lie in
the T4 cells at all, but elsewhere in the network-in the
cells that nourish them as they develop and interact with them
later in their lives. A virus that infects a macrophage may thus
be far more deadly than one that kills a T cell.
Ralph Steinman of The Rockefeller University pointed out
that traveling immune cells, called dendritic cells, only re
cently recognized to be infectable with HIV, may carry HIV
back to regions in the spleen and lymph glands where T
lymphocytes are often first stimulated during an immune
response. HIV-infected dendritic cells conceivably could mal
function, thus reducing the efficacy of the helper T cell re
sponse; or the infected dendritic cells might transmit HIV to
the T cells with which they must interact physically to induce
immunity.
Cells lining blood vessels in many organs, added Siamon
Gordon of Oxford University's Sir William Dunn School of
Pathology, are members of the macrophage lineage. They may
also be infected and then serve as widely distributed reser
voirs of HIV.
In the bone marrow, he went on, a form of mature macro
phage with many fingerlike projections sits at the center of
developing monocytes, apparently nourishing them. They're
CD4-positive, presumably they're infectable, and they sit
close to other cells which can be infected, Dr. Gordon said,
making them "an incredible opportunity for the secondary
spread of the virus."
He presented a very persuasive scenario for the means by
which an AIDS virus might rapidly spread its descendants
across an entire network of immune cells, and it is tempting
to take it for granted that this is how the infection works. But
the mechanism is still only a theory. Since the first report in
1986 showing that HIV could infect monocytes inside an AIDS
patient, there has been very little further direct evidence
clinical evidence-that cells of this class are infected outside
the brain.
SCIENCE vs. AIDS: Defining the Battle Lines
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Two views of how scien
tists identify cells that are
producing the HIV virus.
The top photo illustrates a
method called immunocy
tochemistry. An antibody
(immuno) to a component
of the HIV virus is iso
lated from infected pa
tients, or it is made in mice
using the monoclonaf anti
body approach. The ·anti
body is then added to a
preparation of cells (cyto)
here shown by the shady
oval profiles, each of
which is one cell nucleus.
The antibody is coupled to
an enzyme which then
chemically produces a col
ored product. Two anti
body labeled cells, in
other words, cells carrying
HIV protein, are arrowed.
The bottom photograph
illustrates a method called
in situ hybridization. In
this, molecuiar biology is
used to make a comple
mentary copy of the HIV
messenger RNA, which
must be made to translate
the virus's genetic infor
mation into HIV proteins
(see p. 42). The copy is
modified with radioactive
atoms so that it can be
used to detect HIV mes
senger RNA in any test
sample. When the radioac
tive probe finds the mes
sage of the virus in the
cell, many black spots are
produced over the cell.
Photographs supplied
by Drs. Harm Bos and
Erik Langhoff of The
Rockefeller University.
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IN THE BRAIN,
ANOTHER PUZZLE

E

arly in the infection, the AIDS virus infiltrates the brain.
Even before the immune deficiency arises, said Dr. Broder,
many AIDS patients begin to show neurological abnormali
ties, both in brain scans and in psychological tests.
No one knows exactly how HIV reaches the brain. Infected
T cells or monocytes could carry it there. Inside the brain, HIV
infects macrophage-class cells known as microglia, which nor
mally may perform a nursing function-perhaps nourishing
brain cells or clearing away spent chemical signals. Whether
or not HIV infects other kinds of brain cells is a matter of
debate.
The brain damage that results can sometimes be reversible:
AIDS dementia can recede among patients taking the antiviral
drug AZT. And the physical damage is minor, he added.
Pathologists often remark at autopsy that the visible damage
is inappropriately slight in the brains of patients who were
severely demented before death.
The mysteries are amenable to study. The products of mac
rophages of the nervous system, and their effects on the brain,
I/constitute a key area for research," said Dr. Fields.
Another fertile area for study is the difference between the
people infected with HIV who feel healthy and those who are
beginning to succumb. Fqr example, Dr. Hirsch reported his
studies of asymptomatic AIDS patients from Greece and the
United States. When they felt healthy, their white blood cells
were able to kill about half of their own HIV-infected cells in a
laboratory dish. But when they developed Pneumocystis
pneumonia, these responses (as well as other immune func
tions) dropped dramatically._ When they took AZT, the labo
ratory activity of their white cells revived.
Myron Essex of the Harvard School of Public Health also
described his studies of people who are infected with HIV but
appear well. Those who did not progress to develop AIDS (or
the related syndrome ARC) during the two years of this study
had an intriguing property in common: They produced anti
bodies against a particular small region of the HIV coat pro
tein. Would this explain how people remain healthy during
infection? Could it perhaps form a basis for treatment?
SCIENCE vs. AIDS: Defining the Battle Lines
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COUNTERATTACKS
<�

X

Social ·measures: ,By ,1985, all blood· §citnples in the United

States. were being tested for evidence of HN infection. This
has led to a great decrease in the risk of transfusion. "Safe
sex" -the use of condoms and selectivity in choosing sex
partners-can also reduce the risk:. In·San Francisco, a mas
sive pul:>lic education proj�ct dramaticallyreduced the proppr
tion ofw1y· men testing J.'O�itive for HIV;infection during the
course·of four years. Signs of AIDS infection were detected in
more than one in five male homosexuals newly tested for the
antibody in 1982. The prevalence dropped below one fa a
hundred gay men tested.in 1986.
Vaccines: The AIDS virus itself cannot be used as a vaccine
becaµ.SfJt is invariablytfatal. A weaken��!er killed vi�s, �s
used·in··some influenza.and polio vaccines/may be too risky
to use for vaccinating healthy people (although Jonas Salk,
developer of a polio vaccine, is trying it as a way to boost the
immune response in people who already have AIDS). Two
artifici�l AIDS vaccines are currently under testing in human
volunteei:s in the Unite�;States. Both USfc� virus harmless to
humans, which is ge11etically engineereu to contain a small
fragment of HIVs protein coat as an immune stimulus.
In March 1987, a French researcher announced that he had
injected a small group of volunteers in Zaire, and himself,
with a "vaccine" consisting of inactivated virus. They all de
veloped antibodies against the virus, and some also showed
an incr,ease in 'the activity·of T lymphpcytes. All three pro
posed vaccines provoke the production of antibodies, but it is
too soon to say whether these can prevent the disease.
In England, . testing has begun on another sort of vaccine,
which incorporates a protein from the viruss core (rather than
from its outer coat).
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WHY NOT A VACCINE?

P

eople do not succumb to the human immunodeficiency
virus simply because their bodies fail to recognize its
presence. Very early in the infection, AIDS patients do react
to the virus. They naturally produce antibodies, well-charac
terized proteins that recognize HIV and should lead to its
defeat.
In most cases, these antibodies, which are known as neu
tralizing antibodies, easily conquer an infection. In fact, many
vaccines work by intentionally provoking their creation. Vac
cines provide the immune system with an innocuous first
introduction to a pathogen (as sometimes do reminders that
are known as booster shots). If the agent appears later as an
infection, the immune system can respond quickly. It re
sponds first with antibodies, which both initiate an antiviral
response and remember the virus for years.
But the first antibodies against HIV are not as good as the
name they are given. They fail to neutralize the virus, either
in cell culture or, evidently, inside the body. This confounding
fact provides one main reason why the best strategy against a
viral disease, a vaccine, proves unexpectedly elusive in the
case of AIDS.
In 1984, when HIV was isolated, the head of the United
States Department of Health and Human Services cheerily
predicted there would be an AIDS vaccine in two years. Four
years later, in a quick show-of-hands vote at the Seven Springs
conference, only about half of those present felt there will be
an AIDS vaccine in ten years, and no one would bet on five
years.
The AIDS virus presents a daunting challenge for vaccine
developers. Its protein coat is heavily masked by complex
sugars. It mutates rapidly, giving descendant viruses an op
portunity to escape an immune response designed against
the parent virus. Furthermore, the virus tends to hide out
inside cells where an immune system can't see it under any
circumstances.
History provides some discouraging precedents, Dr. Ko
prowski remarked as the discussion of vaccines began at
Seven Springs. Progress against livestock lentiviruses-which
SCIENCE vs. AIDS: Defining the Battle Lines
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RETROVIRUSES
Nearly 80 years ago, an unusual visitor
came to the laboratory of a young cancer
researcher, Peyton Rous, at The Rockefeller
Institute for Medical Research (now The
Rockefeller University). A chicken breeder
arrived at the lab, accompanied by his hen,
which had a malignant tumor called a sar
coma on its leg.
Rous removed the tumor, filtered off the
cells, and injected other chickens with the
remaining liquid. They developed similar
tumors. Rous decided that an agent too
small to be seen under the microscopes of
1911, perhaps a virus, was at fault. His idea
was greeted with resounding silence at the
time. But he was right.
Some viruses that cause human disease,
such as the agents that cause chicken pox or
hepatitis, are made of the same genetic ma
terial that acts as a blueprint for human
cells: deoxyribonucleic acid, or DNA.
These viruses act by inculcating themselves
directly into the cells they infect. Many tu
mor viruses, such as the Rous sarcoma vi
rus, are made of an alternative kind of
genetic material: ribonucleic acid, or RNA.
When human (or chicken) cells divide,
they copy their DNA into more DNA. Ge
netic information in the DNA is tran
scribed into messenger RNA, which then is
translated into protein. The protein carries
out the functiQn of the gene. In animals,
the flow of information is DNA to RNA
(and then to pr otein) and not the other way
around. So how could an RNA virus ever
proliferate in an animal cell?
The puzzle was solved only in 1970,
when David Baltimore of MIT and Howard
Temin of the University. of Wisconsin dis
covered an enzyme, reverse transcriptase,
peculiar to RNA viruses. These viruses
use it to translate their genetic code "back
wards" into DNA. Thus their name:
retroviruses.
Retroviruses became a mainstay of bio
technology because they allow scientists to
isolate genes, by starting from readily ac
cessible messenger RNA in cells, and also
to insert new genes into cells. Many retro-

42

Internal Viral Protein

Reproductive Enzymes
Reverse Transcriptase

Proteins of Envelope

RNA Genetic Material

viruses, in addition to the chicken Rous
sarcoma virus, were found in animals. But
to medical science they were nothing more
than interesting curiosities until 1980,
when Robert Gallo and his coworkers at the
NIH reported that a retrovirus could cause
a rare leukemia in humans. Then, in 1983,
the retrovirus that causes AIDS came to
light.
The genetic material of the HIV virus,
diagrammed here with wavy lines, encodes
reproductive enzymes, internal virus pro
teins, and other envelope proteins. Their
assembly into new virus particles is dia
grammed on page 44. Additional HIV
genes that play a regulatory role in virus
production are diagrammed on page 46.
Every vertebrate species studied for re
troviruses has been found to be susceptible
to at least one. Some retroviruses are ap
parently harmless, a number of them cause
cancer, and others cause a wide range of
noncancerous degenerative diseases such
as AIDS.
SCIENCE vs. AIDS: Defining the Battle Lines
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are in the same class of pathogens as HIV-has been negligi
ble, despite a great deal of money and effort, because of the
same properties that are outsmarting the AIDS researchers.
The visna virus of sheep, a very close relative of HIY,
mutates so rapidly that (as a population) it slips away from a
vaccine undaunted. Another sheep lentivirus that causes a
neurodegenerative disease known as caprine arthritis enceph
alitis provokes so-called neutralizing antibodies that do not
neutralize inside the animal at all.
On the other hand, Dr. Koprowski noted, veterinary vac
cines against rabies and herpes can protect animals without
provoking a trace of neutralizing antibodies. Presumably the
vaccine elicits other forms of protection such as T-cell
mediated immunity. Its easy to test such vaccines in animals,
by taking the chance they will work. Testing a vaccine against
a uniformly fatal disease using human volunteers is another
matter entirely.
Nonetheless, some human volunteers are already part of
studies directed at developing an AIDS vaccine. In Zaire,
Daniel Zagury of the Pierre and Marie Curie University of
Paris has injected himself and a small group of healthy volun
teers with a prototype vaccine made by genetic engineering. It
incorporates a portion of the HIV coat (a protein called gp160)
into vaccinia, the virus used to vaccinate against smallpox.
Afterwards, Dr. Zagury and his volunteers developed an
antibody response against HIV, and in laboratory tests, the
white blood cells of some of those who had received the
vaccine were able to kill cells infected with the virus. These
responses have lasted for longer than a year. But would they
protect any of the volunteers against a real HIV infection? The
only way to arrive at an answer would be by infecting vacci
nated individuals with live virus in order to determine if the
vaccine is protective.
In the United States, the Federal government and six medi
cal centers are recruiting volunteers for different studies using
direct injection of viral coat proteins, either gp160 or its sub
unit gp120, as a vaccine. The question is whether these vac
cines will provoke any better response than the neutralizing
antibodies that fail to protect AIDS patients in the first place.
These misnamed neutralizing antibodies bind to part of the
viral protein tailed gp120, which is apparently the protein
SCIENCE vs. AIDS: Defining the Battle Lines
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OPERATING PLAN
FOR A RETROVIRUS
Like all viruses, retroviruses consist of a
genetic core, which contains two single
strands of genetic material wrapped in pro
tein, and an outer coat or envelope, a mem
brane studded with glycoproteins. An
infecting retrovirus also carries along its
own enzymes. (See p. 42.)
Having infected a cell, a retrovirus uses
its own enzymes to reverse transcribe its
own genetic material into DNA and insert

AIDS virus
beginning to
assemble
Cell surface
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it into the cell's genetic sequence. At some
later point, it uses the host's machinery,
under the direction of viral signals, to du
plicate its genetic code and to transcribe
this code into messenger RNA and protein
so that it can assemble new copies of itself.
Somehow, the genetic material and core
proteins of the new viruses congregate near
the cell's envelope and bud outwards to
form new viruses.

Budding of
the AIDS virus

l

Release of
infectious
AIDS virus

I
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''key' ' on the virus coat that initially fits the lock of the CD4
protein on an immune cell before th� virus opens it and enters.
Parts of this gp120 protein represent one of the few sites on
the virus coat that are conserved; that is, remain unchanged
by mutation.
Evidently, conserved sites are preserved by nature because
they are integral to the function of the virus. In order to create
a workable vaccine, its desirable to use such conserved regions
of a viral coat as a target so that the virus cannot escape the
vaccine by mutating.
It's likely, speakers at Seven Springs predicted, that vaccines
against this conserved region of gp120 will not be completely
successful in themselves. First of all, there are theoretical
reasons why they may have untoward effects. In a sense, the
neutralizing antibodies that bind to the conserved fragment of
gp120 may partly resemble CD4 itself, much as any lock a key
will open must resemble any other lock it will also open. Will
large numbers of antibodies raised against a viral protein that
binds to a T cell interfere with molecules that should do so
normally?
It would take a large number of antibodies to do the job.
Using CD4 as the basis for an antiviral strategy, raising anti
bodies against the viruss recognition site, or "key," requires
the molecular equivalent of outnumbering the enemy more
than ten to one. It may be impractical to achieve this inside the
human body. Finally, there is no proof that these antibodies
could prevent transmission of HIV from one infected cell to
another.
Recent research points to another site on the virus coat that
is more variable, but which may also be vital to the virus's life
cycle. Dani Bolognesi of Duke University told the Seven
Springs conference about his work with this site, called the N
site, which was discovered by injecting animals with gp160 or
its subunit gp120. They produced antibodies different from
the neutralizing antibodies that have been seen routinely.
More of these alternative antibodies were later found, in small
amounts, in some AIDS patients.
Antibodies that bind to the N site appear not to prevent the
virus from initially binding to a cell, but they do block its later
fusion to the cell wall and prevent the formation of syncytia.
Researchers studying the N site believe it is involved in a
SCIENCE vs. AIDS: Defining the Battle Lines
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GENES OF THE AIDS VIRUS
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gag

pol

Genetic engineering has provided a de
tailed genetic knowledge of HIVl and
HIV2. T he functions of most of the virus's
genes are known, though exactly how they
work is not.
HIV contains three genes common to all
retroviruses: env, pol, and gag. Env en
codes the instructions for making HIV's
outer envelope. Gag encodes the informa
tion for the inner protein in its cylindrical
core, and pol contains the code for the vi
rus's own enzymes involved in such key
steps as r�verse transcription. (See page
42.)
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In addition, HIV's genome contains a
number of novel genes (many of them re
cently renamed). Together, they create a
sophisticated system to control the virus's
reproduction.
Some of the novel genes, such as NEF
(formerly 3' orf), appear to slow down
the- production of new virus. Other genes
seem to enhance the virulence of the AIDS
virus. VIF (formerly sor) increases its
ability to infect new cells. TAT and REV
(formerly called trs/art) regulate the pro
duction of new HIV's. Another gene, VPR,
has unknown functions as yet.
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structural change whereby the virus anchors firmly to the cell
wall after docking onto CD4; perhaps it helps to "tum" the
"key" after it is inserted in the lock.
Antibodies directed against this site on the virus are no
more likely than antibodies against the other gp120 site to
form a useful vaccine in themselves. Dr. Bolognesi has been
looking for versions of these antibodies in a laboratory worker
accidentally infected with HIY. He found that, after about a
year, the HIV isolates inside the patient had begun to mutate
in ways that could escape the antibodies directed against the
N site.
Antibodies are only a small part of the immune response,
of course. On one arm· of the immune system, white cells that
arise from the bone marrow manufacture antibodies; on the
other arm, white cells that come from bone marrow and pass
through the thymus become T cells which kill viruses.
T hese two recognition systems don' t even "see" a virus in
the same way, Jay Berzofsky of the NCI pointed out. T cells
never see the virus coat floating free in the bloodstream; they
see pieces of it on the surface of another immune cell that has
digested and processed the virus. Perhaps, he reasoned, it is
possible to bypass antibodies entirely and design a vaccine
that will stimulate T cells.
Which fragments of the virus tend to emerge on the surface
of an antigen-presenting cell, where the T cells can find them?
Dr. Berzofsk y addressed the question by asking what
structural properties are common to the molecule fragments
known to stimulate a reaction from helper T cells. About three
out of four such fragments, he has found, are helical, with one
face of the helix having an affinity for water and the other face
being hydrophobic, or water-repellant. "This structure," he
remarked, "would tend to chemically stabilize a protein on
the surface of the target that the helper cell must recognize."
Using computer modeling, Dr. Be rzofsky has been
analyzing the AIDS virus coat for chemical sites that match
this two-sided helical pattern. To be useful for a vaccine, he
reasoned, such sites should also come from a part of the viral
coat known not to mutate frequently, and should not be
heavily masked by complex sugars. He found two molecule
fragments on HIV's glycoprotein coat that appeared to fit these
criteria.
SCIENCE vs. AIDS: Defining the Battle Lines
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Scanning electron micro
scope views of two of the
other cell types that can be
infected with HIV: macro
phages (top) and dendritic
cells (bottom). Like helper
lymphocytes, some macro
phages and dendritic cells
can express the T4 or CD4
molecule. Recall that T4 is
the lock recognized by the
gp120 protein key on the
virus, permitting infection
of the T4-bearing cells.
The macrophage is a
phagocyte which actively
scavenges, engulfs, or eats
(phagocytoses) organisms.
In some cases, the macro
phage is permissive and is
used as a site for intracell
ular microbial growth.
The immune interferon
that is produced by T4
helper lymphocytes makes
macrophages less permis
sive or more microbicidal.
The dendritic cell is a
sentinel cell which takes
up small amounts of for
eign materials or antigens.
The cell then moves ac
tively to find T cells that
recognize antigenic frag
ments on the dendritic cell
surface. This surface con
sists of many long sheet
like or spiny processes
(veils, dendrites) which
are used to probe the envi
ronment for T cells. Once
an antigen-specific T cell
is bound, the T cell starts
to multiply and produce
lymphokines like immune
interferon.
Photographs supplied
by Ors. Gilla Kaplan and
Ralph Steinman of The
Rockefeller University.
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Dr. Berzofsky was able to test a vaccine made from one of
these fragments on Dr. Zagury and ,some of his volunteers in
Zaire. In laboratory tests, T cells from Dr. Zagury himself and
eight of his healthy volunteers produced a strong immune
response against HIV-infected cells after injections with Dr.
Berzofskys trial vaccine. But the upshot of the study was
discouraging: Dr. Berzofsky's ''new' ' site that stimulates Tcells
turned out to be identical to the viral site recognized by
neutralizing antibodies. It only underscores, he remarked,
how few antigenic sites, or epitopes, this virus gives human
researchers to work with.
Other viruses than HIV have the habit of changing their
coats slightly to evade vaccination, but many of them also have
enough antigenic sites on their surface that multivalent
vaccines-designed to seek out a number of sites-can
generally provide protection. Given HIV's generally high
mutation rate, its own paucity of recognition sites "augurs
very ill if you play it out," mused Barry Bloom of the Albert
Einstein College of Medicine. If you immunize a patient
against one of these few known antigenic sites, he predicted,
it's reasonable to expect that inside any patient the vims will
eventually mutate at that site, escape the immune response,
and you will have gained nothing.
Even if, by magic, researchers could produce a fail-safe
vaccine today, remarked Richard Lerner of Scripps, it would
be difficult to establish whether or not it could work. For a
sexually transmitted disease, where and how would you
inoculate? In its venereal form, HIV may spread rampantly
before it is visible to immune cells or antibodies in the blood.
At any rate, any sensible person, vaccinated or otherwise, will
try mightily to avoid catching the AIDS virus. In that
circumstance, how long will it take, testing how many
volunteers, to decide that a vaccine is effective?
"I go to fifteen to twenty-five AIDS meetings a year," Dr.
Koprowski said. "All of them tum around how to improve the
vaccine. We should put great pressure on the SIV people
[researchers studying a monkey vims closely related to HIV]
to move with great speed to test vaccines."
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DRUG TREATMENTS
As yet there is no cur�for AIDS. The�ohly drug approved
fiby the Food and·Drug Administration for AIDS treat
ment, 3' Azido2', 3'Dideoxythymidine (AZT or zidovudine),
slows the progression of the disease and relieves some symp
tomsfor as long as it is taken. But it has serious side effects.
A large number of potential anti-AIDS medicines are in
clinical testing, both inside pharmaceutical companies and in
multicenter trials sponsored by the National Institutes of
Health. About 4,000 patients have been enrolled in the NIH
trials since January 1988.
Drugs under testing include:
AZT: Approved by the. FDA in Marcb)987, after a study
showed only one death among 145 patients taking the drugfor
seven months, as against nineteen deaths among the 137
people who took a placebo. It is now sold by Burroughs
Wellcome under the brand name Retrovir. AZT ultimately
depletes the white blood cell count, which makes it unsatisfac
tory as a sole treatment.)t is currently beingtested in combi
nation with other anti- AIDS drugs, an�f also in individuals
who are infected with HIV but have not yet developed symp
toms of AIDS.
ddC (dideoxycytidine): Similar to AZT in action, but caus
ing different side effects: neurological symptoms such as
weakness and defects i11 the sense of touch. ddC improv�s
immune cell counts and. body; weight. iri patients who have
taken it. Being tested in schedules that alternate ddC with
AZT, to limit side effects, and also in combination with other
drugs such as interferon.
De xtran sulfate: A sugarlike compound which seems to
inhibit the virus from binding to cells.
Interferon and other cytokines (prodqc!� of healthy T cells):
Immune-system boosters that may retard tlte progress of the
AIDS-associated cancer, Kaposis sarcoma.
Ampligen: Another immune booster, it restores the func
tion of some immune cells and is thought to control virus
replication.
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can' t resist pointing out the irony," remarked Dr. Broder.
''Four years ago, vaccines were considered the way to go,
and drugs again st AIDS were considered inherently
impossible.' '
Today the reverse seems to be the case. About thirty drug
candidates are being tested on AIDS patients. One of them,
AZT or 3'Azido2', 3'Dideoxythymidine, has been shown to
have some effects in retarding the progress of the disease in
human beings, even though it is not a cure.
Most of the drugs currently considered for AIDS have been
pulled down from the shelf and dusted off-the products of
abortive drug development in pharmaceutical companies,
which could find no use for them earlier. Better treatments
may arise from research specifically directed at interrupting
some part of HIV's life cycle. In the near term, Dr. Broder said,
the best prospects seem to be drugs that can prevent HIV
from translating its genetic blueprint into new virus particles,
since this requires a number of events that are used by the
virus and not by most normal cellular genes. Another prospect
would be to prevent HIV from binding to a cell.
Already, a number of laboratories have succeeded in block
ing the viruss entry into cells by flooding a laboratory dish
with artificial versions of the CD4 molecule. Another ap
proach would be to link a toxin to a version of the CD4 site,
killing any virus that grabs it.
"It would be a difficult job for the virus to develop a strategy
to evade this," Dr. Broder pointed out. T hose mutants less
likely to bind to the drug and be destroyed would also be less
likely to lock onto immune cells.
A less specific drug, the polysaccharide dextran sulfate,
may act by interfering physically with the binding of the virus.
Long used safely as an anticoagulant, it is now under testing
against HIV
About 20 compounds exist that can prevent a virus from
creating a DNA version of its own genetic blueprint, which it
must do in order to infiltrate the DNA of the cell it has entered.
Many of them work more or less like AZT: With a simple
chemical modification, such as the addition of an oxygen
atom, biochemists create an abnormal version of a DNA buildSCIENCE vs. AIDS: Defining the Battle Lines
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GM-CSF (granulocyte-macrophage colony stimulating
factor): An immune sy�tem modifier thal}timulates produc
tion of white blood cells. Tested in combination with AZT.
CD4 · agonists: Molecules that mimic the structure of the
molecule called CD4 on the surface of immune cells, with
which the AIDS virus links to gain entry. Five different re
search groups have shown that these molecules can signifi
cantly block the virus in laboratory ciishes. Preliminary
studies show that mo�eys tolerate the drug without obvious
harm. Clinical trials are underway.
Ribavirin: An antiviral drug shown in some studies to
prevent the lymph-gland swelling that progresses to AIDS
and also the development of Pneumocystis carinii pneumonia.
Unfortunately, recent studies show that ribavirin also inhibits
the body reactions nece��ary to convert AZT to its active form,
and therefore can hinder the effectiveness of the only govern
ment-approved AIDS treatment.
Many of these drugs, and a wide variety of other treatments,
are available to AIDS patients on the black market. T his makes
it very difficult to assess AIDS treatments objectively.. Re
searche�s cannot be certc!in whether or f\()t a patient rriay be
concurrently taking another drug that either improves or hind
ers the effects of the drug (or placebo) in the official study.
While many researche,rs are trying to find a way to stop
AIDS itself, it is up to medical doctors to try to fight the other
illnesses that inevitably arise after AIDS infection. Because
the ·imnmne system is �.lready weak, th�y need to find new
treatments in additionfo the standard antibiotics. For exam.::
ple, Henry Murray of New York Hospital reported at Seven
Springs that he and a number of other researchers are testing
the use of immune modifiers such as gamma interferon to
stimulate AIDS patients' ability to fight opportunistic infec
tions. It is these infections, not the HIV infection itself, that
are ultimately fatal.
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ing block that cannot form the chemical bond needed to ex
tend the DNA molecule. The virus adds AZT to the DNA
polymer, and the polymer stops growing.
Because the virus relies on a cell's own enzymes to construct
its DNA transcript, it is totally vulnerable to such a strategy.
In vitro, AZT can inhibit the replication of HIV at doses ten to
twenty fold lower than the doses that impair the survival of
human cells themselves.
But such drugs do interfere with cells' own DNA manufac
ture, and so cause some harm, because they do stop cells from
dividing or repairing damage to their genetic material. Studies
are now underway to test alternating AZT and ddC as a way
to control the virus without disabling side effects such as nerve
disorders or anemia.
These drugs are the mainstays for the near future, Dr.
Broder said. There are a number of other ways in which HIV
may be vulnerable to defeat by drugs:
D Reverse transcriptase: This protein translates HIV's RNA
genetic code into the form that can be inserted into the
human cells genes. Because it is unique to viruses, a drug
that inactivated it might do no harm whatever to human
cells.
D The TAT gene: In tissue culture, TAT seems to allow HIV to
gear up its production of new viruses. The protein through
which TAT has its effects has been identified, and ways may
be found to block it. TAT is essential for virus production.
D The REV gene: AIDS viruses use REV to manufacture
structural proteins, such as the viral coat. Drugs that block
REV could also block the virus's life cycle.
D Glycosylation inhibitors: These chemicals can prevent the
virus from chemically adhering complex sugar molecules to
its exterior. Because the dense layer of sugar molecules that
coat an AIDS virus appear to be one way it evades recogni
tion by the immune system, finding a way to leave the virus
coat "naked" could be a very effective strategy.
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ight years on, this is most of �hat we know about the
science of AIDS. If the questions seem to outweigh the
statements, consider the epidemic that terrified America in
the other half of this century.
It was 1916. Public hygiene had begun to defeat diseases
such as diphtheria and typhoid in American cities and, as they
would a half-century later, many people began to regard
medical science as all but invincible. Suddenly, for no evident
reason, an outbreak of polio swept across New York City,
striking people without regard to any kind of distinction.
Despite being a victim of the disease, Franklin Delano
Roosevelt won the 1932 presidential election and became a
vital symbol of courage during a long period when almost
nothing was known about the polio virus. It took nearly 40
years to develop an effective vaccine.
By 1981, the year when a few male homosexuals in New
York died of tenuous rare infections, most Americans took for
granted that high-tech medicine had made intractable epi
demics a thing of the past. Nature brought them up short.
It is now clear that AIDS will have a far greater impact on
the world than anyone dreamed in 1981. We may have to
accommodate it in the long term, as we accommodate cancer,
mental illness, and poverty. But in contrast to the struggle
against polio, we have started off knowing much more, and
our tools are far better.
Because HIV uniquely strikes at our ability to combat infec
tions, what scientists must learn as they defeat it will unques
tionably have a major impact on medical science at large.
Because of AIDS, someday we will understand better how to
identify and confront other known viral diseases-and, prob
ably, many more not yet linked to known viruses. AIDS re
search will certainly improve our understanding of the normal
immune system, and of other diseases in which it goes wrong.
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